Overview

Measurement of Plasma and Intracellular Concentrations of Raltegravir

Status:
Completed
Trial end date:
2011-06-30
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to analyze and compare plasma and intracellular concentrations of Raltegravir (RAL) in blood plasma and in peripheral blood mononuclear cells, using high performance liquid chromatography (HPLC).
Phase:
N/A
Details
Lead Sponsor:
University of Nebraska
Treatments:
Raltegravir Potassium